BEVACIZUMAB

Brand name:

• Mvasi®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Amgen Australia Pty Limited

Condition/indication:
(therapeutic use)

• Metastatic colorectal cancer Epithelial ovarian, fallopian tube, or primary peritoneal cancer, cervical cancer, Stage IV glioma, non-small cell lung cancer (NSCLC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (Minor submission)

Comment:

No further action, please see BEVACIZUMAB link in Related Medicines below.

Other PBAC consideration:

• BEVACIZUMAB

Submission received for:

November 2020 PBAC meeting

Opportunity for consumer comment:

Open 26/08/2020 and close 07/10/2020 (see PBS Website)

PBAC meeting:

Held on 04/11/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

18/12/2020

Lodgement of required documentation:

15/01/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable